Skip to main page content

Machine Learning Quantification of Fluid Volume in Eyes with Retinal Vein Occlusion Undergoing Treatment with Aflibercept: The REVOLT study

What:
Paper Presentation | Présentation d'article
When:
2:22 PM, Friday 16 Jun 2023 (7 minutes)
Where:
Québec City Convention Centre - Room 307 AB | Salle 307 AB
How:

Authors: Mohammad A. Khan1, Simrat Sodhi2, Samantha Orr3, Austin Pereira4, Netan Choudhry31McMaster University, 2Oxford University, 3VRMTO, 4University of Toronto.

Author Disclosures: M.A. Khan:   None.  S. Sodhi:   None.  S. Orr:   None.  A. Pereira:   None.  N. Choudhry:    All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Topcon, Optos PLC, Bayer, Allergan, Hoffman La Roche, Johnson & Johnson, Novartis, Carl Zeiss Meditec, Ellex, Topcon, Optos & Carl Zeiss Meditec.

 

Abstract Body: 

Purpose:   Retinal vein occlusions (RVOs) are the second leading cause of vascular blindness, where anti-VEGF agents are among the first-line treatment options. Recent developments in AI models have given promise in OCT fluid segmentation and predictive value in anti-VEGF treatment outcomes; however, there are currently no trials demonstrating machine learning with swept-source OCT images in concordance with OCT analysis for RVO patients, to further elucidate pathology and relationship to visual acuity outcomes. The purpose of this study is to investigate the combined relationship between schema, retinal fluid and layer thickness measurements with visual acuity outcomes for RVO patients and derive insights into disease pathology.   

Study Design:   Phase IV, retrospective, proof of concept, single center study   

Methods:   SS-OCT data were used to assess retinal layer thicknesses and quantify both intraretinal fluid (IRF) and subretinal fluid (SRF) using a deep learning-based, macular fluid segmentation algorithm for 49 eyes with RVOs. Patients received 3 loading doses of 2 mg intravitreal aflibercept injections (IAI) and then were put on a treat-and-extend regimen. Image analysis was performed at baseline, 3-month, and 6-month follow-up. Baseline OCT morphological features and fluid measurements were correlated using the Pearson correlation coefficient (PCC) to changes in BCVA to determine which features most impacted change in BCVA at 6 months. Areas of non-perfusion in OCTA images at baseline were also correlated with change in BCVA at 6 months   

Results:   A combined model incorporating thickness in the outer-plexiform layer (OPL), retinal nerve fiber layer (RNFL) and presence of IRF had the strongest overall correlation for CRVO (PCC=0.865, p<0.05). For BRVO, the addition of IRF to the OPL-Inner Nasal model had a strong correlation (PCC=0.803, p<0.05). Baseline ischemic index in the deep capillary complex (DCP) demonstrated notable correlation with 6-month change in BCVA for CRVO (PCC=0.9101, p<0.001 and BRVO (PCC=0.9200, p<0.001) for BCVA.   

Conclusions:   A combined model of IRF volume, OPL and RNFL layer thicknesses, alongside ischemic indices provide the best correlation to BCVA changes. Combined fluid and layer segmentation of OCT images provides clinically useful biomarkers for RVO patients. These results give insight into the pathology of RVOs, describing the relationship between DCP ischemia & OPL/RNFL thickness in BCVA outcomes.

Presenter
University of Toronto
Resident Physician
Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages